Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PGD | P52209 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122819 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL4728437 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL2126263 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL7151302 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL1591176 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL6665411 | 1.00 | PDE4A (0.52) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL1569332 | 0.92 | PDE4A (0.62) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL5268306 | 0.92 | PDE4A (0.62) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL2912046 | 0.92 | PDE4A (0.62) | PDE4ALMNAL3MBTL1USP2SLCO1B1 | |
| SCHEMBL20576207 | 0.92 | PDE4A (0.62) | PDE4ALMNAL3MBTL1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946744-A1 | NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1999-10-06 | — | — | EP | claimed |
| WO-1998022610-A1 | NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1998-05-28 | — | — | WO | claimed |
| CN-118947730-A | Plant treatment products and related methods | 美国赛多美科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-110678076-B | Plant treatment products and related methods | 美国赛多美科技有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-20230304998-A1 | CELLULAR MATERIAL DETECTION PROBES | FluoretiQ Limited (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4146849-A1 | CELLULAR MATERIAL DETECTION PROBES | Fluoretiq Limited (GB) | 2023-03-15 | — | — | EP | disclosed |
| US-10745395-B2 | Compounds for their use as drugs for the treatment and/or the prevention of infection(s) caused by biofilm-forming bacteria | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-08-18 | — | — | US | disclosed |
| US-20180030047-A1 | COMPOUNDS FOR THEIR USE AS DRUGS FOR THE TREATMENT AND/OR THE PREVENTION OF INFECTION(S) CAUSED BY BIOFILM-FORMING BACTERIA | UNIVERSITE D'ORLEANS (FR) | 2018-02-01 | — | — | US | disclosed |
| EP-3186253-A1 | COMPOUNDS FOR THEIR USE AS DRUGS FOR THE TREATMENT AND/OR THE PREVENTION OF INFECTION(S) CAUSED BY BIOFILM-FORMING BACTERIA | Centre National De La Recherche Scientifique (FR) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030434-A1 | COMPOUNDS FOR THEIR USE AS DRUGS FOR THE TREATMENT AND/OR THE PREVENTION OF INFECTION(S) CAUSED BY BIOFILM-FORMING BACTERIA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2016-03-03 | — | — | WO | disclosed |
| WO-2013075227-A1 | β-GLUCOCEREBROSIDASE CHAPERONES | THE HOSPITAL FOR SICK CHILDREN (CA) | 2013-05-30 | — | — | WO | disclosed |
| US-20080269285-A1 | Novel Compounds of the Family of Iminosugars, Uses Thereof for Trewating Lysosomal Diseases, and Method for Preparing Same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-10-30 | — | — | US | disclosed |
| EP-1893201-A1 | NOVEL COMPOUNDS OF THE FAMILY OF IMINOSUGARS, USES THEREOF FOR TREATING LYSOSOMAL DISEASES, AND METHOD FOR PREPARING SAME | The Centre National de la Recherche Scientifique (FR) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006136714-A1 | NOVEL COMPOUNDS OF THE FAMILY OF IMINOSUGARS, USES THEREOF FOR TREATING LYSOSOMAL DISEASES, AND METHOD FOR PREPARING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-12-28 | — | — | WO | disclosed |
| EP-0946744-B1 | NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES | IDM IMMUNO DESIGNED MOLECULES (FR) | 2004-08-18 | — | — | EP | disclosed |
| EP-0946744-A1 | NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1999046243-A1 | PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF HYDROXYPYRROLIDINES FROM AMINO ACIDS AND PRODUCTS THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5801247-A | Process for the enantioselective synthesis of hydroxypyrrolidines from amino acids and products thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1998-09-01 | — | — | US | disclosed |
| WO-1998022610-A1 | NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES | I.D.M. IMMUNO-DESIGNED MOLECULES (FR) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030047-A1 | COMPOUNDS FOR THEIR USE AS DRUGS FOR THE TREATMENT AND/OR THE PREVENTION OF INFECTION(S) CAUSED BY BIOFILM-FORMING BACTERIA | CHRM1, FPR1, NOX1 | PDE4A 3784/4885LMNA 2358/4885L3MBTL1 424/4885 |
| US-20080269285-A1 | Novel Compounds of the Family of Iminosugars, Uses Thereof for Trewating Lysosomal Diseases, and Method for Preparing Same | GBA1, GAA, MAN2B1 | PDE4A 1704/4885LMNA 1256/4885L3MBTL1 856/4885 |
| US-10745395-B2 | Compounds for their use as drugs for the treatment and/or the prevention of infection(s) caused by biofilm-forming bacteria | CHRM1, FPR1, FPR3 | PDE4A 2879/4885LMNA 2341/4885L3MBTL1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.